Merck KGaA to stick with Crispr gene-editing tech
Merck KGaA (MRK.XE) said late Tuesday that it has no plans to change its position with regards to Crispr technologies, after the publication of two studies on Monday that led to a sharp fall in shares of companies in the sector.
Crispr is a gene-editing technique that makes precise changes to genes linked to certain diseases. The two studies published on Monday in Nature Medicine suggested that cells altered through Crispr could increase the risk of cancer.
"We see the tremendous potential use of Crispr in both research and therapeutics applications," said Udit Batra, member of the executive board at Merck KGaA and chief executive of the life-sciences business at the company.
"[It] is an emerging technology, and research supported by our tools will be required to understand mechanisms like those published in Nature Medicine," Mr. Batra added.
Dow Jones Newswires reported on Tuesday that Bayer AG (BAYN.XE) would remain invested in its joint venture with CRISPR Therapeutics AG
Cosebia Therapeutics. The long-term alliance has received an investment of $300 million, Bayer said Tuesday.
Published at Wed, 13 Jun 2018 06:17:00 +0000